✦ LIBER ✦

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

✍ Scribed by Rosti, Gianantonio; Castagnetti, Fausto; Gugliotta, Gabriele; Palandri, Francesca; Martinelli, Giovanni; Baccarani, Michele

Book ID: 111869620
Publisher: Informa plc
Year: 2010
Tongue: English
Weight: 264 KB
Volume: 51
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428191003637282

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nilotinib monotherapy induced complete r

Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib

✍ Sekimizu, Masahiro; Yamashita, Yuka; Ueki, Hideaki; Akita, Nobuhiro; Hattori, Hi 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 109 KB

Use of dasatinib and nilotinib in imatin

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

✍ DeAngelo, Daniel J.; Attar, Eyal C. 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 324 KB

Comparing nilotinib with dasatinib as se

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis

✍ Griffin, James D.; Guerin, Annie; Chen, Lei; Macalalad, Alexander R.; Luo, Jiayu 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 305 KB

PCN75 ECONOMIC EVALUATION OF DASATINIB I

PCN75 ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB

✍ J.J. Orozco Giraldo; J.E. Valencia; S. Garrido Lecca; E.C. Aiello 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

Fasting glucose improvement under dasati

Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib

✍ M. Breccia; M. Muscaritoli; L. Cannella; C. Stefanizzi; A. Frustaci; G. Alimena 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB